Evidence map›Paper›PMID 30842604›Full record

ArticleLeukemia2019

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

C S Chim, S K Kumar, R Z Orlowski, G Cook, P G Richardson, M A Gertz, S Giralt, M V Mateos, X Leleu, K C Anderson

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Emerging agents and regimens for multiple myeloma.Journal of hematology & oncology · 2020
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

C S ChimDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong. jcschim@hku.hk.
S K KumarDepartment of Medicine, Mayo Clinic at Rochester, Rochester, MN, USA.
R Z OrlowskiDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G CookHaematology & Myeloma Studies, Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
P G RichardsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
M A GertzDepartment of Medicine, Mayo Clinic at Rochester, Rochester, MN, USA.
S GiraltDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
M V MateosDepartment of Haematology, University Hospital of Salamanca, Salamanca, Spain.
X LeleuHopital La Mileterie, part of the Academic Hospital of Poitiers (CHU), Poitiers, France.
K C AndersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of this article the authors noted that the MRD data under the Table 1 column "Remark" of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Identifiers

PMID30842604
PMCPMC7608453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.